In cancer patients with brain metastases and type 2 diabetes, those using GLP-1 drugs had a 37% lower risk of death over 3 years. Significant mortality benefits were linked to semaglutide and ...

In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD ...

Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: ...

Children who used the weight loss drug liraglutide in a late-stage trial lost significantly more weight than children who got a placebo, according to a new study. Doctors say it can be extremely ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it ...

Alternatives to Ozempic for Weight Loss This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Ozempic is an ...

In recent years, diabetes advocacy groups have called for greater attention to measures beyond glycated hemoglobin when evaluating diabetes drugs, because avoiding hypoglycemia and spending more time ...

An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed ...

The FDA's approval of the glucagon-like peptide receptor agonist marks the first non-insulin drug approved for youth with type 2 diabetes since the approval of metformin for pediatric use in 2000.

June 13, 2011 (updated June 24, 2011) — The US Food and Drug Administration (FDA) today warned healthcare professionals to closely monitor patients with diabetes receiving liraglutide injections ...